Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Bupropion · Wellbutrin Xl, NSC-758686

Small molecule · Inhibitor of norepinephrine transporter (SLC6A2) and dopamine transporter (SLC6A3) · developed by Bausch

Approved FDA, Aug 2003

BHC Developer

4 Registered trials

What is Bupropion?

Bupropion is an aminoketone antidepressant that weakly inhibits the neuronal reuptake of norepinephrine and dopamine. The drug is also studied in narcolepsy type 1.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Wellbutrin Xl, NSC-758686, Wellbutrin, Aplenzin
Drug type: Small molecule
Targets: norepinephrine transporter (SLC6A2), dopamine transporter (SLC6A3)
Mechanism: Inhibitor of norepinephrine transporter (SLC6A2) and dopamine transporter (SLC6A3)
Pathways: noradrenergic signaling, dopaminergic signaling
Therapy area: Neurology, Psychiatry
Developer: Bausch (BHC)
Also in trials of: ANRO, AXSM, VRTX
FDA status: Approved as Wellbutrin Xl (August 28, 2003), NDA021515 · FDA label
UNII: 01ZG3TPX31

✅ FDA-approved uses

Major depressive disorder
Seasonal affective disorder

From the indications section of the FDA label (version of Feb 10, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02129751	Phase 4	Major Depressive Disorder	Not yet recruiting	BHC
NCT06223880	Phase 4	Major Depressive Disorder	Recruiting	AXSM
NCT04388189	Phase 4	Major Depressive Disorder	Withdrawn	ANRO
NCT07584434	Phase 1	Narcolepsy Type 1 (NT1)	Recruiting	VRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Major Depressive DisorderNarcolepsy Type 1 (NT1)

Other drugs acting on SLC6A2 / SLC6A3

Atomoxetine FDA approved Solriamfetol FDA approved CTx-1301-Dexmethylphenidate Phase 3 PDC-1421 Phase 2

More from Bausch

Adapalene / Benzoyl Peroxide / Clindamycin FDA approved Brodalumab FDA approved Halobetasol Propionate And Tazarotene FDA approved IDP-118 FDA approved IDP-126 FDA approved Lifitegrast FDA approved Perfluorohexyloctane FDA approved Plecanatide FDA approved Rifaximin FDA approved Timolol FDA approved BL1107 Phase 2 BL1332 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind Bupropion

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z